b-02

RAD51 Inhibitor B02 (B02) (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM.

EAPB-0202, the demethylated metabolite of EAPB0203, demonstrates significant in vitro activity against A375 cells when compared to the reference drugs fotemustine and imiquimod.

OSUAB-0284 is an inhibitor of bacterial topoisomerase. It exhibits significant activity against staphylococci, particularly methicillin-resistant Staphylococcus aureus (MRSA). The compound exerts its antibacterial effect by inhibiting bacterial topoisomerase and may be used in research on infections caused by drug-resistant bacteria, including MRSA.

DOTA-ALB-02 is a ligand that binds with albumin and acts as an FAP inhibitor (FAPI). When labeled with 177Lu, DOTA-ALB-02 demonstrates high affinity for FAP, enhancing tumor uptake and retention, and it has a significant tumor-to-nontarget ratio. It is used in PET/CT and SPECT/CT imaging for detecting cancer, particularly advanced stages.

Compound ALBB-026121, with CAS No. 852916-95-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound ALBB-026121 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound ALBB-025549, with CAS No. 61251-99-8, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound ALBB-025549 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound ALBB-025585, with CAS No. 2653-14-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound ALBB-025585 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

GFB-024 is a humanized antibody targeting CB1, which can be used to study obesity.

RCB-02-4-8, an ionizable cationic lipid designed for the formulation of lipid nanoparticles (LNPs), enhances mRNA delivery with proven effectiveness in increasing lung transfection efficiency in mice [1].

MSB-0254 is a human monoclonal antibody (mAb) that targets VEGFR2/KDR/CD309. It inhibits the invasion, migration, and vasculogenic mimicry (VM) formation of U251 and primary glioma cells. Additionally, MSB-0254 suppresses the growth of U251 and GL261 cell-transplanted tumors. It reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 is applicable to research on advanced solid tumors.

MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. It exhibits potent antitumor activity by killing GD2-expressing target cells through complement-dependent cytotoxicity (CDC). In EL-4-luc xenograft mouse models, MORAb-028 significantly reduces tumor growth. This compound is applicable for melanoma cancer research.

EMB-02 is a bispecific antibody targeting both PD-1 and LAG-3. It inhibits the downregulation of T cell activation and proliferation mediated by PD-1 and LAG-3, showing potent anti-cancer properties.

Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.

Epacadostat (INCB 024360) is an oral, potent and selective IDO1 inhibitor with IC50 value of 71.8 nM.

CCB02 is a selective CPAP-tubulin interaction inhibitor (IC50: 689 nM) with anti-tumor activity, showing no inhibition on cell cycle- and centrosome-related kinases, nor affecting the phosphorylation status of Aurora-A, CDK2, Plk1, Plk2, and CHK1.

Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.

AKOS B029051, with CAS No. 2221-13-8, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. AKOS B029051 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

ART-CHEM-BB B025267 is the upregulator of utrophin production with EC50 of 1.8 μM and can be used in research on the treatment of Duchenne muscular dystrophy.

Alisporivir (Debio-025) is a cyclophilin A inhibitor that disrupts the interaction between CypA and NS5A. It exhibits anti-hepatitis C virus (HCV) activity in vivo and in vitro, inhibits the replication of MERS and SARS coronaviruses, and promotes antigen-specific CD8(+) T cell activation.

B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins.

KB02-JQ1 is a potent and specific proteolysis targeting chimera (PROTAC) that specifically degrades BRD4, acting as a molecular glue. It does not degrade BRD2 or BRD3. The mechanism of action involves covalent modification of the E3 ligase DCAF16, thereby promoting BRD4 degradation. Importantly, KB02-JQ1 demonstrates enhanced stability and durability in facilitating protein degradation within biological systems. The compound forms a complex with the ubiquitin E3 ligase ligand KB02 through a linker, resulting in the formation of KB02-JQ1[1].

KB02-SLF is a PROTAC-based nuclear FKBP12 degrader, also known as a molecular glue, that facilitates the degradation of nuclear FKBP12 by covalently modifying DCAF16, an E3 ligase. SLF acts as a linker, binding to the ubiquitin E3 ligase ligand KB02, thus forming KB02-SLF[1] and enhancing the longevity of protein degradation in biological systems.

FCOB02 is a monoamine oxidase B (MAO-B) ligand. It can be labeled as [18F]FCOB02, serving as a 4-methylcoumarin-like targeting probe. [18F]FCOB02 demonstrates high affinity for MAO-B, with an IC50 of 10.68 nM. It is utilized for specific imaging and quantitative analysis of MAO-B in vivo.

(2S)-SB02024 (SB02877) is the S-enantiomer of SB02024 and acts as a Vps34 inhibitor.